Satomi · 2022 · Frontiers in nutrition
24 weeks of glucoraphanin intake and ALT
Would ALT differ in healthy middle-aged adults whose liver enzyme levels were near the upper limit of normal?
Human · randomized double-blind controlled trial
Key findings
ALT comparison at study end
Median ALT changed from 36 to 29U/L in the GLR group and from 35 to 30U/L in the placebo group. The baseline-adjusted between-group comparison at 24 weeks had p=0.041.
No difference in other measures
There were no significant between-group differences in AST or blood glutathione.
Participant characteristics
The study examined liver enzyme markers near the upper limit of normal in healthy middle-aged adults.
ALT · Baseline and Week 24
Median at each time point · U/L
Between-group p = 0.041 after baseline adjustment · 35 assigned to each group
Healthy middle-aged adults · GLR 60 mg/day
Read the original paper and sources ↓View values and units
| Group | Value |
|---|---|
| Placebo · baseline | 35 |
| Placebo · week 24 | 30 |
| GLR · baseline | 36 |
| GLR · week 24 | 29 |
Study design
Seventy adults aged 45–65 were assigned, 35 each, to glucoraphanin 60mg/day or placebo. Liver enzymes and blood glutathione, among other measures, were evaluated over 24 weeks.
- Participants
- 70 healthy adults aged 45–65
35 assigned to each group · placebo controlled - Intake and observation
- GLR 60mg/day · 24 weeks
placebo controlled · 35 assigned to each group - Measures
- ALT · AST · glutathione
Study context
This trial involved healthy middle-aged adults with liver enzymes near the upper limit of normal. ALT at the end was compared after adjustment for baseline values.
Original paper and sources
Effects of broccoli sprout supplements enriched in glucoraphanin on liver functions in healthy middle-aged adults with high-normal serum hepatic biomarkers: A randomized controlled trial.
- Journal
- Frontiers in nutrition · 2022 · 9: 1077271
- First published
- 2022-12-22